55752-58-4

Basic information

• Product Name: 2,3-DIMETHYLPHENYLTHIOUREA
• Synonyms: 1-(2,3-DIMETHYLPHENYL)-2-THIOUREA;2,3-DIMETHYLPHENYLTHIOUREA;2,3-DIMETHYLPHENYLTHIOUREA, 98+%;N-(2,3-Dimethylphenyl)thiourea, 98+%;1-(2,3-dimethylphenyl)thiourea
• CAS NO: 55752-58-4
• Molecular Formula: C₉H₁₂N₂S
• Molecular Weight: 180.27
• Mol File: 55752-58-4.mol
• Article Data: 9

Chemical Properties

• Melting Point: 202-204°C (dec.)
• Boiling Point: 294.3°Cat760mmHg
• Flash Point: 131.8°C
• Appearance: /
• Density: 1.2g/cm³
• Vapor Pressure: 0.00164mmHg at 25°C
• Refractive Index: 1.674
• BRN: 3249041
• CAS DataBase Reference: 2,3-DIMETHYLPHENYLTHIOUREA(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIMETHYLPHENYLTHIOUREA(55752-58-4)
• EPA Substance Registry System: 2,3-DIMETHYLPHENYLTHIOUREA(55752-58-4)

Safety Data

• Statements: 25
• Safety Statements: 22-36/37-45
• RIDADR: 2811
• HazardClass: 6.1
• PackingGroup: II
• Hazardous Substances Data: 55752-58-4(Hazardous Substances Data)

Usage

Description

2,3-DIMETHYLPHENYLTHIOUREA is an organic compound that serves as a valuable synthetic intermediate in the chemical industry. It is characterized by its unique structure, which includes a thiourea group attached to a 2,3-dimethylphenyl moiety. 2,3-DIMETHYLPHENYLTHIOUREA plays a crucial role in the synthesis of various pharmaceutically relevant molecules due to its versatile reactivity and functional group compatibility.

Uses

Used in Pharmaceutical Synthesis:
2,3-DIMETHYLPHENYLTHIOUREA is used as a synthetic intermediate for the production of 2-Amino-4,5-dimethylbenzothiazole (A605060), a compound with potential applications in the pharmaceutical industry. It is particularly useful in the synthesis of a series of substituted pyrimido[2,1-b]benzothiazoles, which have been found to exhibit antimicrobial activity. This makes 2,3-DIMETHYLPHENYLTHIOUREA an essential component in the development of new antimicrobial agents to combat drug-resistant infections.
Used in Ion Channel Modulation:
2,3-DIMETHYLPHENYLTHIOUREA is also used as a precursor in the synthesis of 2-Amino-4,5-dimethylbenzothiazole, which has been identified as a potential modulator of small-conductance calcium-activated potassium (SKCa), intermediate-conductance calcium-activated potassium (IKCa), and large-conductance calcium-activated potassium (BKCa) channels. Modulating these channels can have therapeutic benefits in various conditions, such as neurological disorders and smooth muscle dysfunction. As a result, 2,3-DIMETHYLPHENYLTHIOUREA contributes to the development of novel treatments targeting ion channelopathies.

InChI:InChI=1/C9H12N2S/c1-6-4-3-5-8(7(6)2)11-9(10)12/h3-5H,1-2H3,(H3,10,11,12)

Upstream product

• 1539-20-4 1-isothiocyanato-2,3-dimethylbenzene 
• 83697-76-1 1-benzoyl-3-(2,3-dimethylphenyl)thiourea 
• 532-55-8 Benzoyl isothiocyanate 
• 87-59-2 2,3-Dimethylaniline 
• 1147550-11-5 ammonium thiocyanate 
• 5417-45-8 2,3-dimethylaniline hydrochloride 
• 6160-65-2 1,1'-Thiocarbonyldiimidazole 

Downstream Products

• 79050-49-0 2-amino-4,5-dimethylbenzothiazole 
• 102612-85-1 1-(2,3-Dimethyl-phenyl)-2-methyl-isothiourea; hydriodide 
• 102612-85-1 1-(2,3-Dimethyl-phenyl)-2-methyl-isothiourea; hydriodide 
• 100601-31-8 2-amino-3,4-dimethylbenzenethiol 
• 139331-48-9 2-{3-[4-(4-Fluoro-phenyl)-piperazin-1-yl]-propyl}-5,6-dimethyl-4H-benzo[1,4]thiazin-3-one 
• 119155-47-4 N-(2,3-Dimethyl-phenyl)-morpholine-4-carboxamidine; hydriodide 
• 774544-65-9 N-(2,3-dimethylphenyl)thiazol-2-amine 

Relevant articles and documents

OPIOID RECEPTOR MODULATORS AND USE THEREOF

Disclosed is an in vitro screening method for identifying an antagonist-to-agonist allosteric modifier of a mu-opioid receptor and an in vivo method for confirming that a test compound is such a modifier of a mu-opioid receptor. Also disclosed is a method

A poised fragment library enables rapid synthetic expansion yielding the first reported inhibitors of PHIP(2), an atypical bromodomain

Research into the chemical biology of bromodomains has been driven by the development of acetyl-lysine mimetics. The ligands are typically anchored by binding to a highly conserved asparagine residue. Atypical bromodomains, for which the asparagine is mutated, have thus far proven elusive targets, including PHIP(2) whose parent protein, PHIP, has been linked to disease progression in diabetes and cancers. The PHIP(2) binding site contains a threonine in place of asparagine, and solution screening have yielded no convincing hits. We have overcome this hurdle by combining the sensitivity of X-ray crystallography, used as the primary fragment screen, with a strategy for rapid follow-up synthesis using a chemically-poised fragment library, which allows hits to be readily modified by parallel chemistry both peripherally and in the core. Our approach yielded the first reported hit compounds of PHIP(2) with measurable IC50 values by an AlphaScreen competition assay. The follow-up libraries of four poised fragment hits improved potency into the sub-mM range while showing good ligand efficiency and detailed structural data.

Optimization of 2-aminothiazole derivatives as CCR4 antagonists

A series of 2-aminothiazole-derived antagonists of the CCR4 receptor has been synthesized and their affinity for the receptor evaluated using a [125I]TARC (CCL17) displacement assay. Optimization of these compounds for potency and pharmacokinetic properties led to the discovery of potent, orally bioavailable antagonists.